Agilent Technologies, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00846U1016
USD
148.32
-0.94 (-0.63%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Agilent Technologies, Inc. stock-summary
stock-summary
Agilent Technologies, Inc.
Pharmaceuticals & Biotechnology
Agilent Technologies, Inc. provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business. Its life sciences and applied markets business segment offers instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Its diagnostics and genomics business segment includes the reagent partnership, pathology, companion diagnostics, genomics and the nucleic acid solutions businesses. Its Agilent CrossLab business segment spans the entire lab with its consumables and services portfolio.
Company Coordinates stock-summary
Company Details
5301 Stevens Creek Blvd , SANTA CLARA CA : 95051-7201
stock-summary
Tel: 1 408 3458886
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 154 Schemes (40.2%)

Foreign Institutions

Held by 462 Foreign Institutions (29.94%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Boon Hwee Koh
Non-Executive Independent Chairman of the Board
Mr. Michael McMullen
President, Chief Executive Officer, Director
Ms. Mala Anand
Independent Director
Mr. Hans Bishop
Independent Director
Mr. Paul Clark
Independent Director
Ms. Heidi Kunz
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,738 Million
(Quarterly Results - Jul 2025)
Net Profit:
336 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 36,325 Million (Mid Cap)

stock-summary
P/E

25.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

39.43%

stock-summary
Debt Equity

0.29

stock-summary
Return on Equity

20.80%

stock-summary
Price to Book

5.70